The latest from Medimaps

March 6, 2024

TBS Osteo: a trusted bone health solution in the world’s top hospitals

Newsweek's World's Best Hospitals 2023 list offers a fitting moment to reflect on TBS Osteo™'s reach: the software is present in more than half of these top 250 hospitals, and trusted by 15 of the top hospitals on the list.

September 4, 2023

Medimaps receives EU certification under the Medical Device Regulation

Medimaps has received Medical Device Regulation (MDR) certification from its notified body BSI (CE 2797) for its management system and product portfolio.

November 28, 2022

Medimaps Group appoints Meinhard F. Schmidt as Board Chairman; adds Anne Le Grand and five additional board members

Meinhard F. Schmidt, an international MedTech/BioTech and digital health executive with 25+ years of experience, has been named Board Chairman.

August 13, 2022

Medimaps announces partnership with OsteoSys to bring Trabecular Bone Score to Korea’s leading bone densitometry platform

TBS Osteo™ is available on OsteoSys's Primus Whole Body DXA, the company's high-end DXA scanning product. The agreement expands worldwide access to Medimaps' technology for clinicians across Southeast Asia, Europe, and South America. Financial terms were not disclosed.

March 4, 2022

Medical reimbursement now available for Trabecular Bone Score (TBS), an advanced medtech solution with artificial intelligence capabilities, for osteoporosis fracture risk assessment

Medimaps — the creator of TBS® (Trabecular Bone Score®), the global standard in bone microarchitecture assessment — today announced that CMS reimbursement is now available for TBS Osteo™ for DXA and X-ray imaging.

December 1, 2021

Medimaps Group raises $20 million to expand and commercialize AI product portfolio for bone health assessment utilizing routine medical images

Medimaps announced that it has secured $20 million in an institutional investment round led by Swisscanto Invest by Zürcher Kantonalbank, alongside Swiss Entrepreneurs Fund, Swisscom Ventures, and Verve Ventures. The funds will be used to expand Medimaps' product portfolio with the development and market launch of its patented AI applications for bone health assessment in the US, Europe, Asia, and Latin America. TBS Osteo™ will receive medical reimbursement in the US beginning January 1, 2022.